Chartwell Partners is pleased to announce two additional C-level recruitments to gene therapy company Encoded Therapeutics: Nancy Boman, M.D., Ph.D. as Chief Regulatory Officer and Monique Bobadilla as Chief People and Culture Officer. Funded by world class venture companies including Venrock, ARCH Venture Partners, Matrix Capital Management, and Illumina Ventures, Encoded is a South San Francisco-based biotechnology company developing precision gene therapies for a broad range of genetic disorders with its lead program in Dravet syndrome.
Most recently, Nancy served as Chief Regulatory Officer for gene therapy pioneer AveXis, helping to lead the successful registration and approval of Zolgensma in SMA. Previously, she held Regulatory, Clinical Development and Pharmacovigilance leadership positions with Alder Biopharmaceuticals, Cell Therapeutics, Genentech and Amgen.
Monique spent the last 14 years with Genentech/Roche, most recently serving in multiple leadership positions, including Human Resources South San Francisco Site Lead for the global Product Development organization and Global HR Business Partner for Product Development Regulatory worldwide.
Chartwell Partners is pleased to have recruited three Executive Leadership Team members to Encoded and a fourth announcement is forthcoming.